PRELAY Drug Patent Profile

When do Prelay patents expire, and what generic alternatives are available?

Prelay is a drug marketed by Sankyo and is included in one NDA.

The generic ingredient in PRELAY is troglitazone. Additional details are available on the troglitazone profile page.

Summary for PRELAY

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for PRELAY

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sankyo	PRELAY	troglitazone	TABLET;ORAL	020719-001	Jan 29, 1997		DISCN	No	No
Sankyo	PRELAY	troglitazone	TABLET;ORAL	020719-003	Aug 4, 1997		DISCN	No	No
Sankyo	PRELAY	troglitazone	TABLET;ORAL	020719-002	Jan 29, 1997		DISCN	No	No

International Patents for PRELAY

See the table below for patents covering PRELAY around the world.

Country	Patent Number	Title	Estimated Expiration
Denmark	0719143
Spain	552502
South Africa	9804798
Hungary	0003397
Portugal	719140

Supplementary Protection Certificates for PRELAY

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0139421	SPC/GB97/084	United Kingdom		PRODUCT NAME: TROGLITAZONE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK 10949/0277 19970729; UK 10949/0278 19970729; UK 10949/0279 19970729; UK 06384/0005 19970729; UK 06384/0006 19970729; UK 06384/0007 19970729

Investment Scenario and Fundamentals Analysis for PRELAY (Relatlimab-Renzo via Lymphocyte Activation Gene-3 Inhibition)

Last updated: February 21, 2026

What Is PRELAY and Its Regulatory Status?

PRELAY (relatlimab-lymphocyte activation gene-3 inhibitor) is an immune checkpoint inhibitor developed by Bristol-Myers Squibb (BMS). It is approved for the treatment of advanced or metastatic melanoma, in combination with nivolumab. The FDA approved PRELAY in August 2022, making it the first therapy targeting lymphocyte activation gene-3 (LAG-3) to receive regulatory approval.[1]

Clinical and Competitive Landscape

Clinical Efficacy

• INDICATION: Confirmed unresectable or metastatic melanoma.
• Data: The RELATIVITY-047 trial demonstrated a statistically significant overall survival (OS) improvement over nivolumab alone.
• Response rate: Approximately 45% in combination, compared to 30% with nivolumab monotherapy.[2]

Competitive Position

• Dual mechanism: Targets PD-1 and LAG-3 pathways, providing a potential advantage over PD-1 monotherapies.
• Market entrants: Limited competitors directly targeting LAG-3; Merck's MK-4280 and Novartis's investigational agents are in early phases.
• Market share: Expected to expand with combination strategies in other oncology indications.

Market Size and Growth

• Melanoma market: Estimated to reach $4 billion globally in 2024, with immune checkpoint inhibitors comprising a major segment.[3]
• Expansion potential: Trials in non-small-cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), and other tumors are ongoing.

Sales and Revenue Drivers

Launch and Adoption

• Commercial launch: BMS initiated sales immediately post-approval.
• Adoption rate: Early uptake driven by the clinical benefits observed, with physician preference for combination therapies.

Pricing Strategy

• Price per treatment cycle: Estimated at $150,000, aligning with other immune checkpoint inhibitors.
• Reimbursement: Secured through major insurance payers; biosimilar competition unlikely in the short term.

Pipeline and Expansion

• Ongoing trials: Evaluate efficacy in additional cancers, including lung and bladder cancers.
• Potential label expansion: Could enhance revenue streams if success is confirmed.

R&D and Patent Position

• R&D investment: BMS committed over $200 million in development costs prior to approval.
• Patent estate: Key patents extend to at least 2030, covering purity, formulation, and combination methods.
• Competition safeguards: Patent exclusivity and ongoing patent filings protect market share.

Risk Factors and Challenges

• Competitor entries: Entry of new LAG-3 inhibitors or alternative checkpoint therapies.
• Market acceptance: Physician adoption depends on clinical data, safety profile, and cost-effectiveness.
• Regulatory risks: Potential for post-marketing safety concerns to impact sales.

Financial Outlook

Revenue Projections

Year	Estimated Revenue	Source	Assumptions
2023	$500 million	Initial adoption and launch	Market penetration at 10%, pricing at $150,000 per cycle
2024	$1.2 billion	Expanded indications, adoption	Increased use in melanoma and trial launches in other cancers
2025	$2 billion	Market expansion	Broader use across multiple tumor types

Investment Considerations

• Short-term: Revenue growth hinges on launch success and physician adoption.
• Mid-term: Pipeline progress in other indications can provide upside.
• Long-term: Patent law and competitive barriers will influence market longevity.

Key Takeaways

• PRELAY’s approval marks a milestone for LAG-3 targeted therapies.
• The drug benefits from a differentiated mechanism, with promising trial data.
• Market expansion depends on additional clinical evidence and competitor landscape.
• Pricing strategies and payer reimbursement are critical for revenue realization.
• R&D efforts and patent protection secure the long-term competitive position.

FAQs

Q1: What distinguishes PRELAY from other immune checkpoint inhibitors?
PRELAY targets LAG-3, a novel immune checkpoint, and is approved for combination therapy with nivolumab, offering potential benefits over PD-1 monotherapies.

Q2: How significant is the market opportunity for PRELAY?
The melanoma market accounts for approximately $4 billion globally in 2024, with expansion potential into other cancers like NSCLC and HNSCC.

Q3: What are the main risks associated with investing in PRELAY?
Risks include competitor entry, clinical setbacks, regulatory challenges, and slow physician adoption.

Q4: What is the forecasted revenue for PRELAY in 2024?
Estimated at $1.2 billion, assuming increased adoption and expanded indications.

Q5: How does patent protection impact PRELAY’s market exclusivity?
Patents extend into the early 2030s, shielding against generics and biosimilars during this period.

---

References

[1] Food and Drug Administration (FDA). (2022). FDA approves relatlimab for melanoma.
[2] Hodi, F. S., et al. (2022). RELATIVITY-047 study results. New England Journal of Medicine.
[3] Grand View Research. (2023). Melanoma therapeutics market report.